Sugi Predict

Sugi Predict / Targets / CYP2S1

CYP2S1

Cytochrome P450 2S1 (EC 1.14.14.-) (CYPIIS1) · Q96SQ9 · CYP2S1 on Sugi Atlas →

6,286 patent compounds predicted against CYP2S1, 3,984 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL2954516 SCHEMBL2954516 0.70 3/20
SCHEMBL2753072 SCHEMBL2753072 0.56 3/20
SCHEMBL2752346 SCHEMBL2752346 0.52 3/20
SCHEMBL2752131 SCHEMBL2752131 0.52 3/20
SCHEMBL1165314 SCHEMBL1165314 0.47 3/20
SCHEMBL971260 SCHEMBL971260 0.42 3/20
SCHEMBL2749440 SCHEMBL2749440 0.42 3/20
SCHEMBL2752725 SCHEMBL2752725 0.41 3/20
SCHEMBL2091704 SCHEMBL2091704 0.41 3/20
SCHEMBL971261 SCHEMBL971261 0.40 3/20
Trifluoroacetic Acid Trifluoroacetic Acid (SCHEMBL2566375) 0.90 2/20
Trifluoroacetic Acid Trifluoroacetic Acid (SCHEMBL2592428) 0.90 2/20
Trifluoroacetic Acid Trifluoroacetic Acid (SCHEMBL2570005) 0.89 2/20
SCHEMBL2584612 SCHEMBL2584612 0.79 2/20
SCHEMBL2407878 SCHEMBL2407878 0.74 2/20
SCHEMBL196765 SCHEMBL196765 0.73 2/20
SCHEMBL2580241 SCHEMBL2580241 0.72 2/20
Trifluoroacetic Acid Trifluoroacetic Acid (SCHEMBL2592437) 0.70 2/20
SCHEMBL2582318 SCHEMBL2582318 0.68 2/20
SCHEMBL1180429 SCHEMBL1180429 0.67 2/20

Clinical trials — most relevant to CYP2S1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Effect of the CYP2C19 Polymorphism in Helicobacter Pylori Eradication PHASE4COMPLETED
Activity of Regorafenib in Combination With Chemotherapy in Patients With Advanced Biliary Tract Cancer PHASE1/PHASE2COMPLETED
Efficacy and Safety of 3D185 Monotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma PHASE2NOT_YET_RECRUITING
Phase II Trial of Disulfiram With Copper in Metastatic Breast Cancer PHASE2COMPLETED
RBN-2397 in Combination With Pembrolizumab in Patients With SCCL PHASE1/PHASE2UNKNOWN
Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis PHASE2ACTIVE_NOT_RECRUITING
A Phase I First-in-Human Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of SWA1211 Tablets in Subjects With Advanced Solid Tumors PHASE1RECRUITING
The Antibiotic Rifampin to Reduce High Levels of Blood and Urine Calcium in IIH PHASE1UNKNOWN
Diindolylmethane in Treating Patients Undergoing Surgery for Stage I or Stage II Prostate Cancer PHASE1COMPLETED
2-Methoxyestradiol in Treating Patients With Advanced Solid Tumors PHASE1COMPLETED
A Study of CYP-001 for the Treatment of Steroid-Resistant Acute Graft Versus Host Disease PHASE1COMPLETED
Cocktail Approach for Cytochrome P450 and P-glycoprotein Activity Assessment Using Dried Blood Spot PHASE1COMPLETED
Measurement of Risperidone and 9-Hydroxyrisperidone in Plasma and Saliva nanCOMPLETED
The Clinical and Economic Impact of Pharmacogenomic Testing for Tamoxifen Metabolism in Postmenopausal Women Receiving Tamoxifen for Prevention of Recurrent Breast Cancer nanCOMPLETED
Connecting Breath and Mind for CYP With Long COVID nanUNKNOWN
Gene Expression, Metabolomic, Microbiome, and Calcium Metabolism in Response to Varied Vitamin D Dosages nanCOMPLETED
PhaRmacOgenetics and Therapeutic Drug Monitoring In SchizophrEnia nanNOT_YET_RECRUITING
Cytochrome P450 2D6 (CYP 450 2D6) Genotype and Flecainide Efficacy nanUNKNOWN
Influence of a Combined Pharmacogenetic Score on Through Plasma Voriconazole Concentrations in Haematological Patients nanCOMPLETED
Association of CYP3A4 rs2242480 With Sufentanil Plasma Concentration and PCA Consumption nanCOMPLETED
Drug Metabolizing Enzyme and Transporter Function in Chronic Kidney Disease nanCOMPLETED
Polycystic Ovary Syndrome in Type 1 Diabetes nanNOT_YET_RECRUITING
Replacement of Vitamin D in Patients With Active Tuberculosis nanCOMPLETED
CYP 2C19 Polymorphism and Voriconazole Trough Concentration in Chinese Adult Patients nanUNKNOWN
Developmental Regulation of Proteins Responsible for Transforming Drugs in the Body nanCOMPLETED
CYP2D6 Screening for Adverse Drug Reactions to Codeine in Breast Milk nanCOMPLETED
CYP2C19 Variants and Limonene Metabolism nanRECRUITING
Prospective Cytochrome P450 Genotyping and Clinical Outcomes in Patients With Psychosis nanCOMPLETED
Effects of Genotype on CYP2C9 Drug Interactions nanCOMPLETED
Post-market Study of AMPA Receptor Antagonists for Epilepsy Patients in Hong Kong nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a CYP2S1 binder may also engage these)

ProteinNameSimilarity
Q9DBX6 — 1.000 Q9DBX6 →
E9Q816 — 0.995 E9Q816 →
CYP2W1 Cytochrome P450 2W1 0.988 landscape →
Q29488 — 0.987 Q29488 →
CYP2D6 Cytochrome P450 2D6 0.984 landscape →
A0A087X1C5 — 0.983 A0A087X1C5 →
Q2XNC8 — 0.982 Q2XNC8 →
Q2XNC9 — 0.978 Q2XNC9 →
Q29473 — 0.978 Q29473 →
O18992 — 0.977 O18992 →
O46658 — 0.976 O46658 →
Q64403 — 0.974 Q64403 →
Q01361 — 0.973 Q01361 →
Q64680 — 0.971 Q64680 →
Q9QUJ1 — 0.969 Q9QUJ1 →
P12790 — 0.966 P12790 →
CYP2F1 Cytochrome P450 2F1 (EC 1.14.14.1) (CYPIIF1) 0.965 landscape →
Q8WNE1 — 0.965 Q8WNE1 →
CYP2B6 Cytochrome P450 2B6 0.963 landscape →
Q9QYG5 — 0.963 Q9QYG5 →
P12791 — 0.962 P12791 →
Q2LCM1 — 0.962 Q2LCM1 →
Q8WNW0 — 0.962 Q8WNW0 →
P12789 — 0.962 P12789 →
Q4V8D1 — 0.961 Q4V8D1 →
E9Q5K4 — 0.961 E9Q5K4 →
P15540 — 0.960 P15540 →
P10633 — 0.960 P10633 →
P24456 — 0.960 P24456 →
P11714 — 0.960 P11714 →